Related Experiment Video
Updated: Oct 27, 2025
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Pentraxin 3 concentration is associated with poor outcomes in patients with coronary artery disease: a systematic
William Kamarullah1, Nurcahyani2, Rachmatu Bill Multazam3
1Faculty of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia.
Insights
Elevated plasma pentraxin 3 (PTX3) levels are linked to worse outcomes in coronary artery disease (CAD). This meta-analysis confirms a dose-dependent relationship between higher PTX3 concentrations and increased risk of mortality and major adverse cardiovascular events in CAD patients.
Area of Science:
- Cardiology
- Biomarkers
- Clinical Research
Background:
- Plasma pentraxin 3 (PTX3) is emerging as a potential biomarker for predicting adverse outcomes in patients with coronary artery disease (CAD).
- The precise relationship between PTX3 levels and CAD prognosis remains incompletely understood.
- This study aimed to quantify the association between circulating PTX3 concentrations and CAD prognosis.
Purpose of the Study:
- To conduct a dose-response meta-analysis to evaluate the association between plasma pentraxin 3 (PTX3) levels and prognosis in patients with coronary artery disease (CAD).
- To determine if higher PTX3 concentrations correlate with an increased risk of mortality and major adverse cardiovascular events (MACEs) in CAD patients.
Main Methods:
- A systematic literature search was performed across multiple databases (PubMed, EuropePMC, ProQuest, EBSCOhost, SCOPUS, Cochrane Library, Google Scholar) up to April 2021.
- The meta-analysis included 15 studies encompassing 11,365 participants.
- Primary outcomes assessed were all-cause mortality and major adverse cardiovascular events (MACEs).
Main Results:
- High circulating PTX3 concentrations were significantly associated with a greater risk of composite poor outcomes (OR: 1.36 [1.18, 1.54]), mortality (OR: 1.43 [1.15, 1.71]), and MACEs (OR: 1.28 [1.08, 1.48]) compared to low concentrations.
- A significant positive dose-dependent relationship was observed, with a 32% increase in the odds of poor outcomes for every 1 ng/mL increment in PTX3 (aOR: 1.32 [1.21, 1.43]).
- These findings remained consistent across meta-regression analyses and subgroup analyses, indicating robustness.
Conclusions:
- This dose-response meta-analysis demonstrates a significant positive association between circulating PTX3 concentration and the risk of adverse outcomes in patients with CAD.
- Elevated PTX3 levels serve as a reliable indicator of poor prognosis in individuals with coronary artery disease.
- The findings support the potential utility of PTX3 as a prognostic biomarker in CAD management.
Background:
The amount of plasma pentraxin 3 (PTX3) is gradually being considered as a novel biomarker in forecasting poor clinical outcomes in patients with coronary artery disease (CAD). However, very little is known about the connection between PTX3 and CAD. This dose-response meta-analysis was carried out to quantify the relationship between circulating PTX3 concentration and CAD prognosis.
Methods:
A systematic literature search was conducted using PubMed, EuropePMC, ProQuest, EBSCOhost, SCOPUS, Cochrane Library, and Google Scholar up until April 2021. The primary outcome of this study consisted of mortality and major adverse cardiovascular events (MACEs).
Results:
The current meta-analysis comprised 15 studies with a total of 11.365 participants. High circulating PTX3 concentrations were associated with a higher risk of composite poor outcomes as compared to low circulating PTX3 concentrations (OR: 1.36 [1.18, 1.54], p < 0.001; I2 = 86.69%, Pheterogeneity<0.001), mortality (OR: 1.43 [1.15, 1.71], p < 0.001; I2 = 87.58%, Pheterogeneity<0.001), and MACEs (OR: 1.28 [1.08, 1.48], p < 0.001; I2 = 35.86%, Pheterogeneity = 0.08) in patients with CAD. Consistent results were obtained during meta-regression analyses and in all examined subgroups. The adjusted odds ratios (aORs) for composite poor outcomes increased by 32% per 1 ng/mL increment (OR: 1.32 [1.21, 1.43]) in line with the dose-response meta-analysis.
Conclusion:
A significant positive dose-dependent association between circulating PTX3 concentration and the risk of poor outcomes in patients with CAD was found in this dose-response meta-analysis.
More Related Videos
06:16Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
10:12A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay
Published on: August 8, 2013
Related Concept Videos
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:30Coronary Artery Disease III: Clinical Manifestations
01:27Peripheral Artery Disease III: Interprofessional Care
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
01:30Coronary Artery Disease I: Introduction